NAFDAC Gives Update On Withdrawn Boots Dermacare Medication

The National Agency for Food and Drug Administration and Control has announced that it has been informed by the United Kingdom’s Medicine and Healthcare Product Regulatory Agency, of the withdrawal of Boots Dermacare 1% w/w Hydrocortisone Ointment, by Boots Company PLC because Pseudomonas aeruginosa was discovered in the medication.

NAFDAC stated that Boots Dermacare 1% w/w Hydrocortisone is used to reduce swelling, treat eczema, allergic contact dermatitis and insect bites.

According to NAFDAC, pseudomonas aeruginosa is a Gram-negative bacteria; which can worsen initial symptoms.It is capable to cause erythematous lesions, irritation and pus-filled pimples.

The withdrawn Boots medication is produced by Boots UK Limited; it has an active ingredient-Hydrocortisone 1% w/w; with batch numbe-1DD. The medication will expire in August 2023.

Importers, wholesalers, and retailers are therefore advised by NAFDAC to stop the importation, distribution, and use of the recalled batch of Boots Dermacare 1% w/w hydrocortisone ointment.

NAFDAC has advised that Patients already using the affected lot of Boots Dermacare 1% w/w Hydrocortisone Ointment to stop it’s use and seek medical attention.

NAFDAC has therefore urged Patients and healthcare providers to report adverse effects they experienced using these products to the nearest NAFDAC office.